Q&A: Com­mer­cial vet­er­an Su­san Sweeney mo­bi­lizes decades of drug launch ex­pe­ri­ence at Am­gen

Su­san Sweeney spent more than two decades in drug com­mer­cial­iza­tion at Bris­tol My­ers Squibb be­fore mov­ing to Am­gen in Sep­tem­ber 2019, just a few months be­fore the Covid-19 pan­dem­ic.

Sweeney, now Am­gen’s se­nior VP of glob­al mar­ket­ing, ac­cess and ca­pa­bil­i­ties, didn’t know of course what was about to hap­pen any more than any­one else, but her long­time drug launch ex­per­tise – which in­clud­ed block­busters like Op­di­vo and Eliquis – meant she’d weath­ered more ups and downs in phar­ma com­mer­cial­iza­tion than most.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER